The identification of patients at high risk for recurrent disease after treatment for early-stage cervical cancer

Objective: To investigate prognostic factors in patients with recurrent cervical cancer after treatment of early-stage disease in order to identify high-risk patients who might benefit from alternative treatment strategies. Study Design: The authors retrospectively analyzed clinical and pathology data from 130 recurrent cervical cancer patients after surgical treatment for early-stage disease. Patients were compared with a recurrence-free control group matched for age, FIGO Stage, and adjuvant treatment. Univariate and multivariate Cox regression analyses were performed to determine prognostic factors for recurrence and survival. Results: Of 889 patients, 130 (14.6%) developed recurrent disease after primary treatment for early-stage cervical cancer. Local or loco-regional metastasis was observed in 45%, distant metastasis in 31%, and combined pelvic and distant metastasis in 24%. Median survival after recurrence was 12 months (range 1-107 months). Median five-year survival was 96% in the control group and 29% in the recurrence group. Tumor size ≥ 40 mm and lymph node metastasis were independent unfavorable prognostic factors for overall survival (OS) and disease-free survival (DFS). The number of positive lymph nodes (≥ one) and bilateral occurrence of pelvic lymph node metastasis were associated with adverse clinical outcome. Conclusions: Tumor size ≥ 40 mm and lymph node metastasis were independent unfavorable prognostic factors in surgically treated, early-stage cervical cancer patients. The combination of these factors was particularly associated with recurrence. Future trials should focus on the role of alternative adjuvant treatment strategies in patients at high risk of recurrent disease (e.g., by chemotherapy, immunotherapy or combinations thereof).

Cervical cancer; Surgical therapy; Neoplasm recurrence; Survival; Disease-free survival.

[1] Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al.: “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012”. Int. J. Cancer, 2015, 136, E359.

[2] Pecorelli S.: “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 103.

[3] Monk B.J., Herzog T.J.: “The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination”. Am. J. Obstet. Gynecol., 2007, 197, 337.

[4] Pieterse Q.D., Kenter G.G., Maas C.P., de Kroon C.D., Creutzberg C.L., Trimbos J.B., Ter Kuile M.M.: “Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study”. Int. J. Gynecol. Cancer, 2013, 23, 1717.

[5] Harding Y., Ooyama T., Nakamoto T., Wakayama A., Kudaka W., Inamine M., et al.: “Radiotherapy- or radical surgery-induced female sexual morbidity in stages IB and II cervical cancer”. Int. J. Gynecol. Cancer, 2014, 24, 800.

[6] Landoni F., Maneo A., Colombo A., Placa F., Milani R., Perego P., et al.: “Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer”. Lancet, 1997, 350, 535.

[7] Rotman M., Sedlis A., Piedmonte M.R., Bundy B., Lentz S.S., Muderspach L.I., Zaino R.J.: “A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study”. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 169.

[8] Sedlis A., Bundy B.N., Rotman M.Z., Lentz S.S., Muderspach L.I., Zaino R.J.: “A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study”. Gynecol. Oncol., 1999, 73, 177.

[9] Hellebrekers B.W., Zwinderman A.H., Kenter G.G., Peters A.A., Snijders- Keilholz A., Graziosi G.C., et al.: “Surgically-treated early cervical cancer: Prognostic factors and the significance of depth of tumor invasion”. Int. J. Gynecol. Cancer, 1999, 9, 212.

[10] Pieterse Q.D., Trimbos J.B., Dijkman A., Creutzberg C.L., Gaarenstroom K.N., Peters A.A., Kenter G.G.: “Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study”. Int. J. Gynecol. Cancer, 2006, 16, 1112.

[11] Sevin B.U., Nadji M., Lampe B., Lu Y., Hilsenbeck S., Koechli O.R., Averette H.E.: “Prognostic factors of early stage cervical cancer treated by radical hysterectomy”. Cancer, 1995, 76, 1978.

[12] Soisson A.P., Soper J.T., Clarke-Pearson D.L., Berchuck A., Montana G., Creasman W.T.: “Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer”. Gynecol. Oncol., 1990, 37, 390.

[13] Rosa D.D., Medeiros L.R., Edelweiss M.I., Pohlmann P.R., Stein A.T.: “Adjuvant platinum-based chemotherapy for early stage cervical cancer”. Cochrane Database Syst. Rev., 2012, 6, CD005342.

[14] Peters W.A. III, Liu P.Y., Barrett R.J., Stock R.J., Monk B.J., Berek J.S., et al.: “Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix”. J. Clin. Oncol., 2000, 18, 1606.

[15] Cadron I., Van G.T., Amant F., Leunen K., Neven P., Vergote I.: “Chemotherapy for recurrent cervical cancer”. Gynecol. Oncol., 2007, 107, S113.

[16] Elit L., Fyles A.W., Devries M.C., Oliver T.K., Fung-Kee-Fung M.: “Follow-up for women after treatment for cervical cancer: a systematic review”. Gynecol. Oncol., 2009, 114, 528.

[17] Monk B.J., Tewari K.S., Koh W.J.: “Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions”. J. Clin. Oncol., 2007, 25, 2952.

[18] Moore D.H.: “Chemotherapy for advanced, recurrent, and metastatic cervical cancer”. J. Natl. Compr. Canc. Netw., 2008, 6, 53.

[19] van den Tillaart S.A., Kenter G.G., Peters A.A., Dekker F.W., Gaarenstroom K.N., Fleuren G.J., Trimbos J.B.: “Nerve-sparing radical hysterectomy: local recurrence rate, feasibility, and safety in cervical cancer patients stage IA to IIA”. Int. J. Gynecol. Cancer, 2009, 19, 39.

[20] Horn L.C., Fischer U., Raptis G., Bilek K., Hentschel B.: “Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer”. Gynecol. Oncol., 2007, 107, 310.

[21] Samlal R.A., Van D.V., Ten Kate F.J., Schilthuis M.S., Hart A.A., Lammes F.B.: “Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes”. Cancer, 1997, 80, 1234.

[22] Creasman W.T.: “New gynecologic cancer staging”. Gynecol.Oncol., 1995, 58, 157.

[23] van den Tillaart S.A., Sramek A., Wasser M.N., Trimbos J.B.: “Barrel index of bulky cervical tumours and intrauterine fluid determined by MRI as additional prognostic factors for survival”. Eur. J. Gynaecol. Oncol., 2013, 34, 208.

[24] Trimbos J.B., Lambeek A.F., Peters A.A., Wolterbeek R., Gaarenstroom K.N., Fleuren G.J., Kenter G.G.: “Prognostic difference of surgical treatment of exophytic versus barrel-shaped bulky cervical cancer”. Gynecol. Oncol., 2004, 95, 77.

[25] Moore D.H.: “Treatment of stage IB2 (bulky) cervical carcinoma”. Cancer Treat. Rev., 2003, 29, 401.

[26] Rydzewska L., Tierney J., Vale C.L., Symonds P.R.: “Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer”. Cochrane Database Syst. Rev., 2012, 12, CD007406.

[27] Eddy G.L., Bundy B.N., Creasman W.T., Spirtos N.M., Mannel R.S., Hannigan E., O’Connor D.: “Treatment of (“bulky”) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group”. Gynecol. Oncol., 2007, 106, 362.

[28] Lapresa M., Parma G., Portuesi R., Colombo N.: “Neoadjuvant chemotherapy in cervical cancer: an update”. Expert Rev. Anticancer Ther., 2015, 15, 1171.

[29] Lai C.H., Chang H.C., Chang T.C., Hsueh S., Tang S.G.: “Prognostic factors and impacts of adjuvant therapy in early-stage cervical carcinoma with pelvic node metastases”. Gynecol. Oncol., 1993, 51, 390.

[30] Inoue T., Morita K.: “The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB”. Cancer, 1990, 65, 1923.

[31] Hsu C.T., Cheng Y.S., Su S.C.: “Prognosis of uterine cervical cancer with extensive lymph node metastases. Special emphasis on the value of pelvic lymphadenectomy in the surgical treatment of uterine cervical cancer”. Am. J. Obstet. Gynecol., 1972, 114, 954.

[32] Takeda N., Sakuragi N., Takeda M., Okamoto K., Kuwabara M., Negishi H., et al.: “Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy”. Acta Obstet. Gynecol. Scand., 2002, 81, 1144.

[33] Le B.G., Mercier M., Woronoff A.S., Guizard A.V., Abeilard E., Caravati- Jouvenceaux A., et al.: “Quality of life in long-term cervical cancer survivors: a population-based study”. Gynecol. Oncol., 2013, 129, 222-8.

[34] Mossa B., Mossa S., Marziani R.: ‘Adjuvant chemotherapy versus radiation therapy after radical surgery in high-risk positive node stage IB/IIA cervical cancer”. Eur. J. Gynaecol. Oncol., 2010, 31, 545.

[35] Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., et al.: “Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity”. Clin. Cancer Res., 2008,

14, 169.

[36] Welters M.J., Kenter G.G., Piersma S.J., Vloon A.P., Lowik M.J., Berends-van der Meer D.M., et al.: “Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine”. Clin. Cancer Res., 2008, 14, 178.

[37] Welters M.J., Kenter G.G., de Vos van Steenwijk P.J., Lowik M.J., Berends-van der Meer D.M., Essahsah F., et al.: “Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses”. Proc. Natl. Acad. Sci. U S A, 2010, 107, 11895.

[38] Jack A., Boyes C., Aydin N., Alam K., Wallack M.: “The treatment of melanoma with an emphasis on immunotherapeutic strategies”. Surg. Oncol., 2006, 15, 13.